Status:
RECRUITING
Spinal Nalbuphine for Analgesia in Total Hip Arthroplasty
Lead Sponsor:
Asklepieion Voulas General Hospital
Collaborating Sponsors:
Anastasios Mpontozis
Conditions:
Total Hip Arthroplasty
Analgesia
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
60 patients ASA I-III, undergoing total hip arthroplasty were randomly assigned, into one of two groups, namely group E (n=30), where levobupivacaine will be administeral intrathecally ; and group N (...
Eligibility Criteria
Inclusion
- Physical status according to American Society of Anesthesiologists (ASA) I-III
- Patients scheduled for total hip arthroplasty
Exclusion
- BMI above 40
- Serious psychiatric, mental and cognitive disorders
- Contraindication for central and/or peripheral nervous blockade
- History of allergic or other adverse reactions on the agents used in the study
- Chronic opioid
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06577155
Start Date
September 1 2024
End Date
June 1 2025
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asklepieion Hospital of Voula
Athens, Ελλάδα (+30), Greece, 16675